Diagnosing pancreatic adenocarcinoma requires a careful combination of imaging, blood tests, and tissue examination, especially since early symptoms are often absent or vague, making timely detection challenging.

Introduction: Who Should Seek Diagnostic Testing and When

Pancreatic adenocarcinoma, the most common type of pancreatic cancer, represents about 95% of all pancreatic cancers and is notoriously difficult to detect in its early stages.^[5] One of the biggest challenges in diagnosing this disease is that there are typically no noticeable signs or symptoms during the early course of illness, which often leads to delays in diagnosis.^[2] By the time symptoms appear, the cancer has often already spread to other parts of the body.

People should consider seeking medical evaluation if they experience certain warning signs. These include yellowing of the skin and eyes, known as jaundice, which happens when the tumor blocks the bile duct.^[3] Other concerning symptoms include persistent pain in the upper abdomen or middle back, unexplained weight loss without trying, loss of appetite, constant fatigue, nausea and vomiting, gas or bloating, and changes in stool color or urine color.^[3] Light-colored stool or dark urine can be particularly telling signs that something is wrong with the digestive system.

Healthcare providers might also suspect pancreatic cancer in patients who have recently developed diabetes without obvious cause or those who suddenly develop pancreatitis, which is inflammation of the pancreas causing severe pain.^[3] Some patients report that their first symptoms were back pain or stomach pain that came and went initially but worsened after meals or when lying down.^[13] Unfortunately, many people develop only vague symptoms up to one year before receiving an actual diagnosis, which highlights how subtle the early presentation can be.

Certain individuals face higher risks and might benefit from discussing screening with their doctor. Risk factors include cigarette smoking, which is linked to as many as one quarter of all pancreatic tumors, as well as obesity, type 2 diabetes, chronic pancreatitis, and having a family history of pancreatic cancer.^[2] People with specific genetic syndromes, such as those associated with the BRCA1, BRCA2, PALB2, and ATM genes, also carry increased risk.^[12] African-Americans, men, and older adults are also at higher risk, with most cases occurring after age 65.^[1][2]

Classic Diagnostic Methods for Identifying Pancreatic Adenocarcinoma

Diagnosing pancreatic cancer is challenging because the pancreas is positioned deep within the abdomen, hidden behind the stomach and other organs, making it difficult to see or feel during routine physical examinations.^[7] When a doctor suspects pancreatic cancer based on symptoms or risk factors, several diagnostic methods are typically employed to confirm the presence of disease and distinguish it from other conditions with similar presentations.

Imaging Tests

Imaging tests play a crucial role in visualizing the pancreas and detecting abnormalities. A helical computed tomographic scan, or CT scan, is one of the most common first-line imaging tools used to identify pancreatic cancer.^[12] This test uses X-rays and computer processing to create detailed cross-sectional images of the pancreas and surrounding structures. The CT scan can reveal the location and size of tumors and help determine whether the cancer has spread to nearby blood vessels or other organs.

Magnetic resonance imaging, or MRI, is another valuable imaging technique that uses magnets and radio waves instead of radiation to create detailed pictures of soft tissues in the body.^[12] MRI scans can be particularly helpful in visualizing the pancreatic ducts and detecting smaller tumors that might be missed on CT scans.

Endoscopic ultrasonography, often shortened to EUS, combines endoscopy with ultrasound technology.^[12] During this procedure, a thin, flexible tube with an ultrasound probe on the end is passed through the mouth, down the esophagus and stomach, to reach the area near the pancreas. Because the probe is positioned very close to the pancreas, it can create highly detailed images. This technique is also valuable because it allows doctors to perform biopsies if suspicious areas are found.

Some medical centers also use PET scans, which involve injecting a small amount of radioactive sugar into the bloodstream.^[20] Cancer cells, which typically consume more sugar than normal cells, show up as bright spots on the scan. PET scans can be helpful in determining whether the cancer has spread beyond the pancreas and can also help assess how well treatment is working.

Blood Tests and Tumor Markers

Blood tests are another important component of pancreatic cancer diagnosis, though they cannot definitively diagnose the disease on their own. One commonly measured substance is CA 19-9, which stands for cancer antigen 19-9.^[12] This is a protein that is often elevated in people with pancreatic cancer. However, CA 19-9 has limitations because it lacks specificity, meaning it can also be elevated in other conditions, and some people with pancreatic cancer do not have elevated levels at all. Despite these limitations, most patients with pancreatic cancer do have an elevated CA 19-9 level at diagnosis, and tracking this marker over time can help doctors monitor disease progression or response to treatment.^[12]

It is important to note that no truly tumor-specific markers exist for pancreatic cancer, which is why blood tests must be interpreted alongside other diagnostic findings rather than used in isolation.^[12]

Tissue Biopsy and Pathological Examination

The most definitive way to diagnose pancreatic cancer is through a biopsy, which involves removing a small sample of tissue from the suspicious area and examining it under a microscope.^[8] Biopsies can be obtained in several ways. During endoscopic ultrasonography, doctors can use a thin needle to extract tissue samples from the pancreas. Other times, biopsies may be performed using CT guidance, where imaging helps guide a needle through the skin to reach the pancreatic mass.

Once tissue is obtained, a pathologist examines it to look for cancer cells and determine the specific type of pancreatic cancer. In pancreatic adenocarcinoma, the cancer develops from cells lining the small tubes, called ducts, that carry digestive juices through the pancreas.^[5] The pathologist can confirm whether cancer is present and provide information about its characteristics, which helps guide treatment decisions.

Additional Diagnostic Procedures

Endoscopic retrograde cholangiopancreatography, abbreviated as ERCP, is sometimes used when there is suspicion of bile duct obstruction.^[8] This procedure uses an endoscope passed through the mouth to reach the area where the bile duct and pancreatic duct empty into the small intestine. Dye is injected through the scope to make the ducts visible on X-ray images, allowing doctors to see blockages or narrowing that might indicate cancer.

In some cases, minimally invasive techniques such as laparoscopy may be used.^[12] During laparoscopy, small incisions are made in the abdomen and a tiny camera is inserted to directly visualize the pancreas and surrounding organs. This can help determine whether the cancer has spread to the abdominal lining or other nearby structures that might not be visible on standard imaging tests. Doctors may also sample fluid from the abdomen during this procedure to check for cancer cells.

Peritoneal cytology, which involves examining fluid from the abdominal cavity for cancer cells, has proven useful in some cases.^[12] In one case series of 228 patients, positive peritoneal cytology had a very high specificity of 98% and a positive predictive value of 94% for determining that the cancer could not be completely removed by surgery, though its sensitivity was only 25%.

Distinguishing Pancreatic Cancer from Other Conditions

One of the challenges in diagnosing pancreatic adenocarcinoma is that its symptoms overlap with many other, less serious conditions. Jaundice can occur with gallstones or hepatitis. Abdominal pain and digestive problems can result from ulcers, gastritis, or chronic pancreatitis. Weight loss and fatigue are nonspecific symptoms that accompany countless illnesses. This is why a combination of clinical evaluation, imaging, blood tests, and tissue analysis is necessary to arrive at an accurate diagnosis and rule out other possible explanations for a patient’s symptoms.

Diagnostics for Clinical Trial Qualification

When patients with pancreatic adenocarcinoma consider participating in clinical trials, they typically undergo additional testing beyond what was required for initial diagnosis. Clinical trials are research studies that test new treatments or combinations of treatments, and they often have specific requirements, called eligibility criteria, that patients must meet before they can enroll.

Staging and Resectability Assessment

Before enrolling in a clinical trial, doctors must thoroughly evaluate the stage of the cancer, which describes how much the disease has grown and spread.^[12] Staging involves detailed imaging tests, typically including high-quality CT scans and sometimes MRI or PET scans. The goal is to determine whether the tumor is confined to the pancreas or has spread to nearby blood vessels, lymph nodes, or distant organs.

Clinical trials often categorize patients based on resectability, meaning whether the tumor can potentially be removed by surgery. Patients may be classified as having resectable disease, where the tumor has not grown into important blood vessels and can be removed; borderline resectable disease, where the tumor has grown close to or into major blood vessels but surgery might still be possible; locally advanced disease, where the cancer has grown too extensively into blood vessels or nearby tissues to allow for safe removal; or metastatic disease, where the cancer has spread to distant organs.^[12] Many clinical trials are designed specifically for patients in one of these categories.

Genetic and Molecular Testing

Modern clinical trials increasingly require genetic and molecular testing of both the patient and the tumor. Germline testing looks at the patient’s own DNA, inherited from their parents, to identify mutations that might affect how the cancer behaves or responds to treatment.^[12] Certain inherited mutations, particularly in genes like BRCA1, BRCA2, PALB2, and ATM, can make pancreatic cancer cells more vulnerable to specific treatments.

Biomarker testing of the tumor tissue itself is also crucial for clinical trial enrollment and treatment selection.^[4] This testing examines the tumor’s biology at a molecular level to identify specific characteristics that might predict response to targeted therapies or immunotherapies. For example, some clinical trials accept only patients whose tumors have high microsatellite instability, abbreviated as MSI-H, or DNA mismatch repair deficiency, known as dMMR, because these tumors may respond to immunotherapy drugs.

Some advanced medical centers are now using novel genetic testing to examine the blood of patients for traces of cancer DNA, as well as testing fluid from the abdomen during laparoscopy.^[20] This approach can help identify patients who might be at higher risk for cancer recurrence after treatment and can guide individualized therapy plans.

Performance Status and Organ Function Tests

Clinical trials typically require patients to have adequate organ function and overall physical condition to tolerate the treatments being studied. This usually involves blood tests to check kidney function, liver function, and bone marrow function by measuring things like creatinine, liver enzymes, and blood cell counts. Patients often need to have a certain performance status score, which is a measure of how well they can carry out daily activities, to be eligible for enrollment.

Additional Specialized Testing

Depending on the specific clinical trial, additional specialized tests may be required. Some trials require repeat biopsies or imaging at specific time points to monitor how the tumor is responding to treatment. Others may require specialized PET scans that use novel tracers to measure metabolic activity or other features of the tumor. Patients considering clinical trial participation should discuss with their medical team what specific tests will be required and what the purpose of each test is in determining eligibility and monitoring response.